Does Rallies show 13F holders for ELV?

Yes. Rallies tracks hedge fund and 13F ownership data for ELV, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ELV research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ELV. It does not provide personalized investment advice.

ELV (Elevance Health) Stock Analysis - Hedge Fund Holdings

Elevance Health (ELV) is a publicly traded Healthcare sector company. As of May 20, 2026, ELV trades at $394.13 with a market cap of $85.58B and a P/E ratio of 15.96. ELV moved -2.37% today. Year to date, ELV is +13.56%; over the trailing twelve months it is -0.38%. Its 52-week range spans $273.71 to $528.52. Analyst consensus is buy with an average price target of $387.47. Rallies surfaces ELV's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ELV stock?

Hedge funds tracked by Rallies that own ELV include Harris Associates, GQG Partners, Baupost Group, D1 Capital, and Cooperman Leon. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Elevance Health.

ELV Key Metrics

Key financial metrics for ELV
Metric	Value
Price	$394.13
Market Cap	$85.58B
P/E Ratio	15.96
EPS	$25.28
Dividend Yield	1.72%
52-Week High	$528.52
52-Week Low	$273.71
Volume	489.80K
Avg Volume	0
Revenue (TTM)	$199.13B
Net Income	$5.66B
Gross Margin	89.36%

Top Hedge Funds Holding ELV

Harris Associates holds 4.80M shares of ELV, changed +0.04% as of Mar 31, 2026.
GQG Partners holds 1.46M shares of ELV, changed +0.00% as of Jun 30, 2025.
Baupost Group holds 1.28M shares of ELV, changed +0.46% as of Mar 31, 2026.
D1 Capital holds 326.41K shares of ELV, changed -43.57% as of Jun 30, 2025.
Cooperman Leon holds 227.90K shares of ELV, changed -33.15% as of Mar 31, 2026.

Latest ELV News

Elevance Health Buy Rating Boosts Target to $498 on 14.5x 2028 Earnings — May 20, 2026
Elevance Health jumps after BofA upgrade to Buy, $435 target on Medicaid margin recovery — Apr 29, 2026
Elevance Health jumps as Q1 beats expectations and management lifts 2026 outlook — Apr 27, 2026
Elevance Health jumps after Q1 beat and higher 2026 adjusted EPS outlook — Apr 23, 2026
Elevance slides despite Q1 beat as $935M CMS accrual sharpens regulatory overhang — Apr 22, 2026

Recent ELV Insider Trades

SCHULMAN AMY W sold 26 (~$7.47K) on Mar 12, 2026.
Kendrick Charles Morgan JR sold 3.20K (~$910.60K) on Mar 6, 2026.
COLLIS STEVEN H bought 3.00K (~$869.52K) on Mar 5, 2026.

ELV Analyst Consensus

16 analysts cover ELV: 0 strong buy, 11 buy, 5 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $387.47.

Common questions about ELV

Who owns ELV stock?: Hedge funds tracked by Rallies that own ELV include Harris Associates, GQG Partners, Baupost Group, D1 Capital, and Cooperman Leon. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Elevance Health.
Does Rallies show 13F holders for ELV?: Yes. Rallies tracks hedge fund and 13F ownership data for ELV, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ELV research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ELV. It does not provide personalized investment advice.